"The successful completion of this study is an important milestone for Dyax and the DX-2930 development program," said Gustav Christensen, President and Chief Executive Officer of Dyax. “Given prior validation of the plasma kallikrein pathway in HAE, we believe DX-2930 has the potential to be a game changer in HAE therapy."
Conference Call & Webcast
|Tuesday, February 25, 2014|
|5:00 p.m. ET|
|Domestic callers, dial 877-474-9501,|
|International callers, dial 857-244-7554,|
|Reference the Dyax conference call;|
Go to the Investor Relations section of the Dyax website ( http://investor.dyax.com/index.cfm) and follow instructions for accessing the live webcast. Please connect to the web site at least 15 minutes prior to the start of the conference call to ensure adequate time for any software download that may be necessary.
Discovered using Dyax’s proprietary phage display technology platform, DX-2930 is a novel, fully human monoclonal antibody inhibitor of plasma kallikrein (pKal). Uncontrolled pKal activity leads to excessive generation of bradykinin, a vasodilator thought to be responsible for the localized swelling, inflammation and pain characteristically associated with HAE. Dyax is currently developing DX-2930 as a subcutaneous injection for the prevention of HAE attacks and expects to initiate a Phase 1b trial mid-year 2014.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts